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Abstract 
Over the past three decades, the number of drugs used during pregnancy increased by 60%. Cluster 
analysis of COPSAC 2010 study showed that antibiotics were prescribed to 21% of included pregnant 
women to treat lower respiratory tract infections (LTRI). The most dangerous for both mother and fetus, 
but although the most rare is community-acquired pneumonia (CAP). However, no antibiotic prescribed 
for CAP applies to category “A” according to FDA classification, which means none of them is safe for 
use in the gestational period.  
Aim. to study changes in PCT level and leukocyte count (Lc) in terms of evaluating the efficacy of 
antibiotic therapy (ABT) in pregnant with CAP.  
Materials and methods. The study included 35 women with a diagnosis of CAP (Group A) and a 
control group of 15 healthy pregnant (Group B). Quantitative determination of the PCT level in the 
serum was performed by chemiluminescence method. In Group A PCT and Lc were measured on 
admission and on the 5th day of therapy. 
Results. The study showed that PCT level measured on admission, unlike the Lc, was higher than in 
Group B ((Med [25–75%]) 0,18 [0,11–0,25] ng/ml vs 0,047 [0,036 – 0,071], p=0,000). And decreased on 
the background of ABT to 0,06 [0,04-0,08] ng/ml (p=0,000). 
Conclusions. Revealed changes in the PCT levels in respond to antibiotic therapy in pregnant with CAP 
can be used as an objective method to evaluate the efficacy of treatment. This can reduce the duration of 
therapy and thus reduce possible negative influence on fetus. 
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1. Introduction  
Over the past three decades, the number drugs used during pregnancy increased by 60%, and 
this figure does not take into account the use of vitamins and mineral complexes. These data 
were obtained by A. A. Mitchell et al., 2011 from the cluster analysis of questioning of more 
than 30 thousand pregnant during the period from 1976 to 2008 [1]. 
At the same, time the Copenhagen Prospective Study on Asthma in Childhood 
(COPSAC 2010) J. Stokholm et al. showed that antibiotics were prescribed to 21% (148) of 
the 706 pregnant women included in the study because of the lower respiratory tract infections 
(LTRI). 
It should be noted that of all LTRI the most dangerous for both mother and fetus, but although 
the most rare is community-acquired pneumonia is (CAP).  
Moreover, unlike the more prevalent acute bronchitis, CAP is an absolute indication for 
antibiotics use either as monotherapy or in combination. The usual course of treatment lasts 
from seven to ten days. However, no antibiotic applies to category “A” according to FDA 
classification, which means none of them is safe for use in the gestational period [2]. 
Therefore, prescribing medications, and in particular antibiotics, in pregnancy is a difficult 
medical problem because it is necessary not only to fight the infection, but also to minimize 
the possible adverse effects on the fetus. 
One of the most effective methods to reduce frequency of antibiotic prescription and duration 
of treatment is by using procalcitonin (PCT), as an objective indicatior of presence and 
severity of bacterial inflammation. 
In 2012, Nilam J. Soni et al. had analyzed 18 clinical trials that compared the efficacy of 
procalcitonin-guided initiation and / or discontinuation of antibiotics in different groups, 
including patients with respiratory tract infections, to standard therapy.  
Analysis showed that the use of PCT in patients with LTRI as in patients from ICU had the 
strongest evidence base. PCT-guided therapy in above-mentioned groups of patients reduced  
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Frequency of prescription and duration of antibiotic use in 
comparison to standard clinical guidelines [3].  
At the same time, authors noted that pregnancy was one of the 
excluding criteria in all of the analyzed studies. Which makes 
impossible to use the obtained data in pregnant patients with 
LTRI and determines the need of further research [4]. 
Recently a number of articles containing the results of PCT 
study in pregnancy have been published. They were dedicated 
to determination of PCT levels in uncomplicated pregnancy 
and to the possibility of its use in preeclampsia and urinary 
tract infections [5, 6]. 
For example, Pacolat C et al., 2011 in their study of PCT at 
different stages of uncomplicated pregnancy showed that the 
levels of this marker in I, II and III trimester did not exceed the 
reference values for non-pregnant women of childbearing age 
[7]. This indicates the fact that it is possible to develop criteria 
for antibiotic initiation and/or discontinuation in pregnant with 
LTRI based on PCT level. 
 
Aim: to study changes in PCT level and leukocyte count (Lc) 
in terms of evaluating the efficacy of antibiotic therapy (ABT) 
in pregnant with CAP. 
 
2. Materials and methods. The study included 35 women 
with a diagnosis of CAP (Group A) and a control group of 15 
healthy pregnant (Group B). All CAP patients were admitted 
to specialized obstetrical department in the period from 
October 2013 to November 2014. Both groups were 
comparable by age and gestational terms (Table 1).  
 
Table 1: 
 
Groups Age Med [25–75%] (years) 
Gestational terms Med 
[25–75%] (weeks) p 
A 25 [19–30] 30 [27–33] <0,05 B 31 [25–37] 35 [34–37] 
 
In all patients from Group A, the diagnosis of CAP was 
confirmed by chest X-rey and assessed as not severe CAP 
according to the Order of Ministry of Health of Ukraine 
№ 128. Ten women had a history of upper respiratory tract 
infection prior to the CAP development. None of the pregnant 
included in the study received antibiotics before hospital 
admission.  
Quantitative determination of the PCT level in the serum was 
performed by chemiluminescence method. In Group A PCT 
and Lc were measured on admission (PCT-1, Lc- 1) and on the 
5th day of therapy (PCT-2, Lc-2). 
All women were informed about the purpose and methodology 
of the study and signed an informed consent. 
Statistical analysis was performed using STATISTICA 
version 6.0 [7]. 
 
3. Results and discussion 
The study showed that PCT level measured on admission to 
clinic was (Med [25–75%]) 0,18 [0,11–0,25] ng/ml. That did 
not exceed 0,25 ng/ml – the threshold for prescribing 
antibiotics developed in previous studies, which excluded 
pregnant. 
This result may be due to physiological immunosuppression 
that develops in pregnancy, as well as to a small area of the 
lung tissue involved in inflammatory process observed in all 
patients of the study group. 
In addition, it is important to take into account that all women 
were admitted on early stages of the disease development due 
to high alertness of doctors towards pregnant women with 
symptoms of LTRI. This, combined with the use of highly 
sensitive methods of quantitative determination of PCT, can be 
another reason for the low values of studied marker we have 
obtained. 
If the upper-mentioned low levels of PCT were identified in 
non-pregnant women, the decision on initiation of antibiotic 
therapy would be delayed. Since the PCT level below 0,25 
ng/ml in the general population indicates a self-limiting 
infection that does not require antibiotics [8]. 
But in pregnancy even a small focus of bacterial inflammation 
can lead to complications such as infection of the amniotic 
fluid and preterm delivery, thus the initiation of antibacterial 
therapy was based on standard clinical criteria, according to 
the Order of Ministry of Health of Ukraine № 128 [9].  
Data on PCT and Lc changes in group A and their comparison 
to Group B are shown in Table 2.  
 
Table 2: 
 
Groups 
PCT-1 Med 
[25–75%] 
ng/ml 
PCT-2 
Med [25–
75%] 
ng/ml 
Lc-1 Med 
[25–75%] 
*109 /l 
Lc-2 Med 
[25–75%] 
*109 /l 
A 0,18 [0,11 0,25]*˄ 
0,06 [0,04-
0,08] 
11,0 [8,2 – 
14,0]#˅ 
8,6 [6,8 – 
10,0] 
B 0,047 [0,036 – 0,071] 9,8 [7,8 – 11,7] 
Notes: * - p<0,05 between visits by Wilcoxon  
 ˄ - p<0,05 between groups by Mann-Whitney  
 # - p <0,05 between visits by Wilcoxon  
 ˅ - p<0,05 between groups by Mann-Whitney 
 
Only PCT, unlike leucocyte count, showed statistically 
significant difference both in comparison between groups and 
visits. 
The credibility of the detected changes in PCT levels shows 
that this marker reflects the response of pregnant with CAP to 
antibiotic therapy. Which indicates that PCT can be used as an 
objective indicator to regulate the duration of antibiotic 
therapy in women during pregnancy. 
 
4. Conclusions 
1. A lower level of PCT in pregnant women, compared to 
the criteria developed for the general population, does not 
exclude the presence of the CAP. It can indicate the small 
area of the lung tissue involved in inflammatory process 
and early stage of the disease. 
2. The possibility of using PCT as an objective indicator for 
antibiotic therapy initiation in pregnant women with CAP 
requires further investigation.  
3. Revealed changes in the PCT levels in respond to 
antibiotic therapy in pregnant with CAP can be used as an 
objective method to evaluate the efficacy of 
treatment. This can reduce the duration of therapy and 
thus reduce possible negative influence on fetus. 
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